George Institute for

The ANGELO study is a clinical trial sponsored by The George Institute investigating opioid-free general anesthesia compared to opioid-based general anesthesia for reducing postoperative nausea and vomiting (PONV) in patients undergoing robotic bariatric surgery. The program combines four approved small-molecule agents: magnesium sulfate, lidocaine hydrochloride, dexmedetomidine (Dexdor), and ketamine (Ketolar). All component drugs are already approved and in clinical use; this trial evaluates their combined application as an opioid-sparing anesthetic regimen in the obesity surgery population. The study represents a repositioning strategy for existing approved medications toward a specific surgical indication where PONV remains a significant postoperative complication. The program is currently active in clinical trial phase, with regulatory status of component drugs already established across major markets including the United States, European Union, and Australia.

Postoperative nausea and vomiting remains a common and costly complication following general anesthesia, particularly in high-risk populations such as obese patients undergoing bariatric surgery. Opioid-induced PONV is a well-recognized phenomenon, and opioid-sparing anesthetic techniques represent an emerging strategy to improve patient outcomes and reduce healthcare costs associated with antiemetic interventions and extended recovery times. The obesity indication is clinically relevant given the rising prevalence of bariatric procedures and the documented higher PONV incidence in this population. The competitive landscape includes established obesity pharmacotherapies (semaglutide, Mysimba) and various anesthetic agents, but the ANGELO study addresses a distinct clinical problem: perioperative management rather than weight loss. The trial's focus on opioid-free anesthesia aligns with broader healthcare initiatives to reduce opioid exposure and associated adverse effects. Success could establish a standardized opioid-sparing anesthetic protocol for high-risk surgical populations, potentially driving adoption across surgical centers and creating value through improved patient satisfaction, reduced complications, and lower total perioperative costs.

Program Composition: ANGELO combines four approved small-molecule agents administered as a multimodal anesthetic regimen:

• Magnesium Sulfate 150 mg/ml (Injectable/Infusion): Nervous system agent; route intravenous; mechanism: NMDA receptor antagonist and neuroprotectant.
• Lidocaine Hydrochloride: Local anesthetic and antiarrhythmic; nervous system class (N01); topical and injectable routes; mechanism: sodium channel blocker.
• Dexmedetomidine (Dexdor 100 micrograms/ml): Alpha-2 adrenergic agonist; sedative-analgesic; intravenous infusion.
• Ketamine (Ketolar 50 mg/ml): NMDA receptor antagonist; dissociative anesthetic; injectable; nervous system class.

Modality: Small-molecule combination therapy. Route: Intravenous (injectable and infusion). Target: Multimodal anesthetic targets including NMDA receptors, alpha-2 adrenergic receptors, and sodium channels. Related Therapies: Opioid-based general anesthesia (comparator); other multimodal anesthetic regimens; antiemetic agents (ondansetron, dexamethasone). First Approval: All component drugs approved decades ago; lidocaine approved in Australia from 1991; regulatory status established across US (FDA), EU (EMA), and Australia (TGA).

United States (FDA): All four component drugs hold FDA approval via multiple NDAs and ANDAs. Lidocaine is approved with 54+ application numbers across multiple sponsors (Teva, Hikma, Amneal, Aurobindo, and others). Dexmedetomidine (Dexdor) and ketamine (Ketolar) are approved. Magnesium sulfate is approved. The ANGELO trial itself (NCT 2025-521047-20-00) is registered but specific IND or trial authorization status not disclosed.

European Union (EMA): Lidocaine approved with multiple MAHs including Plethora Pharma Solutions Limited and Recordati Ireland Ltd.; authorisation dates include 31/01/2025 and 14/11/2019 (EMA product numbers EMEA/H/C/002693, EMEA/H/C/005298). Dexmedetomidine and ketamine are approved. Magnesium sulfate is approved.

Australia (TGA): Lidocaine approved with PBS codes 10209H, 2876J, 4308R; sponsors include Aspen Pharmacare Australia and Bridgewest Perth Pharma; first listed dates 1991-08-01, 2005-06-01, 2024-10-01. All component drugs approved.

China (NMPA): Lidocaine in clinical trials (NCT04439786); other component drug status not yet disclosed.

Japan (PMDA): Regulatory status not yet disclosed.

Trial Authorization: ANGELO study status as investigational program not yet disclosed; component drug use in trial context presumed authorized under existing approvals and trial protocols.

Strategic Implications: The ANGELO study represents The George Institute's strategy to generate clinical evidence supporting opioid-sparing anesthetic protocols in high-risk surgical populations. By combining four well-established, low-cost approved drugs, the program avoids de novo drug development timelines and regulatory risk while addressing a genuine clinical need (PONV reduction in bariatric surgery). Success could establish a standardized protocol adoptable across surgical centers without requiring new drug approvals, reducing implementation barriers.

Competitive Implications: The trial does not directly threaten existing obesity pharmacotherapies (semaglutide, Mysimba), which address chronic weight management rather than perioperative outcomes. However, if opioid-sparing anesthesia reduces postoperative complications and improves bariatric surgery outcomes, it could enhance the overall value proposition of bariatric procedures, potentially increasing surgical volume and indirectly benefiting obesity drug markets. The study may also influence anesthetic practice patterns, reducing opioid consumption in surgical settings—a broader healthcare trend supporting opioid stewardship.

Future Catalysts: Primary catalyst is trial completion and publication of PONV incidence data comparing opioid-free versus opioid-based anesthesia in the bariatric population. Secondary catalysts include adoption by surgical societies in perioperative guidelines, presentation at major anesthesia conferences (ASA, ESRA), and potential expansion to other high-risk surgical populations (gynecologic, orthopedic). Regulatory pathway for the combined protocol (if any formal approval sought) remains unclear and not yet disclosed.

Expected Milestones: Interim or final efficacy data release; publication in peer-reviewed anesthesia journals; potential guideline recommendations; expansion to additional surgical indications or patient populations.